PDGF D Hemidimer Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for bone regeneration, such as using BMP-2 and BMP-7, require supraphysiological concentrations and have limited clinical efficacy due to marginal effects on bone formation, necessitating the development of more effective stimuli for bone marrow mesenchymal stem cell differentiation into osteogenic lineage cells.
Innovation Solution
Administration of a recombinant platelet-derived growth factor D (PDGF D) hemidimer, comprising a full-length PDGF D polypeptide and a C-terminal growth factor domain lacking a CUB domain, to promote the differentiation of bone marrow mesenchymal stem cells into osteogenic lineage cells, utilizing a PDGF D hemidimer or GFD dimer composition to stimulate bone repair and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BMP-2 and BMP-7 are used for bone regeneration, then bone formation is induced, but supraphysiological concentrations are required and clinical efficacy is limited
Solution Approach 1:
The patent changes the biological parameter by switching from BMP-2/BMP-7 growth factors to PDGF-D hemidimer, which activates a different signaling pathway (β-PDGFR/SMAD2/3) that is more efficient at physiological concentrations. This parameter change resolves the contradiction by achieving reliable bone formation without requiring supraphysiological concentrations
Solution Approach 2:
The patent introduces PDGF-D hemidimer as an intermediary substance that mediates bone formation through a more efficient pathway. The hemidimer structure serves as an optimal intermediary that activates osteoprogenitor cells and promotes differentiation into osteoblasts with higher efficacy than BMP-2/BMP-7 at physiological concentrations
2Reliability
If TGF-β and BMP are administered to induce stem cell differentiation, then osteoprogenitor cell commitment is achieved, but marginal effects on bone regeneration are observed
Solution Approach 1:
The patent merges two critical functions into one substance: PDGF-D hemidimer simultaneously acts as a chemoattractant (recruiting osteoprogenitor cells via β-PDGFR activation) and as a mitogen/differentiation factor (promoting cell proliferation and osteoblastic differentiation). This merging resolves the contradiction by achieving both reliable differentiation and high productivity in bone regeneration
Solution Approach 2:
The patent uses a composite structural approach by employing the hemidimer form of PDGF-D, which combines a full-length PDGF-D polypeptide and a C-terminal growth factor domain lacking CUB domain. This composite structure optimizes both cell recruitment and differentiation functions, achieving marginal effects resolution through structural composition
3Reliability
If PDGF D full-length polypeptide is used, then receptor activation is achieved, but CUB domain prevents optimal differentiation signaling
Solution Approach 1:
The patent segments the PDGF-D protein structure by removing the CUB domain from the full-length polypeptide, creating a truncated version that retains receptor activation capability while eliminating the portion that interferes with optimal differentiation signaling. This segmentation resolves the contradiction by separating the functional domains
Solution Approach 2:
The patent extracts and removes the CUB domain from the PDGF-D full-length structure, isolating only the essential C-terminal growth factor domain that is necessary for β-PDGFR activation and osteogenic differentiation. This extraction resolves the contradiction by eliminating the problematic CUB domain while preserving the beneficial signaling functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PDGF D hemidimer composition effectively stimulates the differentiation of mesenchymal stem cells into osteogenic cells, enhancing bone repair and regeneration while inhibiting adipocyte differentiation, thereby addressing the limitations of existing bone regeneration methods.
Implementation Method 1
stimulating the mesenchymal stem cell and/or a progenitor derived therefrom, thereby stimulating the mesenchymal stem cell (MSC) and/or a progenitor derived therefrom
Data Source
AI summary
Methods of treating a subject in need thereof are provided which include: administering a recombinant platelet derived growth factor D (PDGF D) composition to a mesenchymal stem cell of the subject and/or a progenitor derived therefrom, in vivo, or ex vivo, producing a treated mesenchymal stem cell of the subject and/or a progenitor derived therefrom, thereby stimulating the mesenchymal stem cell (MSC) and/or a progenitor derived therefrom. Cells expressing a recombinant PDGF D composition of the present are administered to the subject for in vivo delivery of the recombinant PDGF D composition according to aspects of the present disclosure. Methods and compositions are provided including recombinant PDGF D hemidimer (HD) including a full-length PDGF D polypeptide and a C-terminal growth factor domain of PDGF D, which lacks a CUB domain, promoting regulation of bone marrow MSC differentiation into osteogenic lineage cells.